



Conatus Pharmaceuticals  
Investor Relations Department  
16745 W. Bernardo Drive  
Ste 200  
San Diego, CA 92127  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CNAT**

Last Trade:	5.01
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.12 <span style="color: red;">↓</span> (-2.339%)
Day Range	4.91 - 5.19
52-Week Range	1.45 - 9.40
Volume	378,572

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

*Aug 14, 2017*

[Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis](#)

*Aug 2, 2017*

[Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates](#)

*Jul 26, 2017*

[Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results](#)

*Jul 6, 2017*

[Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of \\$7 Million Payment](#)

*Jun 26, 2017*

[FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC](#)

### Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 4, 2017*

[Quarterly Report \(10-Q\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)